logo
ScreenersREIT EarningsREIT SectorsMarketplaceLearn
Logo

Pulmatrix, Inc.

PULM

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs byā€¦ read more

Healthcare

Biotechnology

9 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$4.71

Price

-6.18%

-$0.31

$5.02

Previous Close

$5.00

Open

Premium

52w Discount
Market Cap

$17.202m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$369k

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$7.930m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$2.17

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$5.604m

$6.152m

Assets

$548k

Liabilities

-

Debt
Debt to Assets

0.00%

-

Debt to EBITDA
Free Cash Flow

-$8.016m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.